0000899243-19-023936.txt : 20190919 0000899243-19-023936.hdr.sgml : 20190919 20190919190535 ACCESSION NUMBER: 0000899243-19-023936 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190917 FILED AS OF DATE: 20190919 DATE AS OF CHANGE: 20190919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Koppel Adam CENTRAL INDEX KEY: 0001578965 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 191102458 MAIL ADDRESS: STREET 1: C/O BROOKSIDE CAPITAL, LLC STREET 2: JOHN HANCOCK TOWER, 200 CLARENDON ST CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schwartz Jeffrey Lawrence CENTRAL INDEX KEY: 0001702957 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 191102459 MAIL ADDRESS: STREET 1: C/O BAIN CAPITAL LIFE SCIENCES, LP STREET 2: 200 CLARENDON STRERET CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BC SW, LP CENTRAL INDEX KEY: 0001786351 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 191102460 BUSINESS ADDRESS: STREET 1: 200 CLAREDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162000 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 191102461 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc. CENTRAL INDEX KEY: 0001773427 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-883-9490 MAIL ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-17 0 0001773427 SpringWorks Therapeutics, Inc. SWTX 0001703031 Bain Capital Life Sciences Investors, LLC 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 0001786351 BC SW, LP 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 0001702957 Schwartz Jeffrey Lawrence C/O BAIN CAPITAL LIFE SCIENCES INVESTORS LLC, 200 CLARENDON STREET BOSTON MA 02116 1 0 1 0 0001578965 Koppel Adam 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 Common Stock 2019-09-17 4 C 0 6078103 A 6078103 I See Footnotes Common Stock 2019-09-17 4 C 0 1053204 A 7131307 I See Footnotes Common Stock 2019-09-17 4 P 0 150000 18.00 A 7281307 I See Footnotes Series A Convertible Preferred Stock 2019-09-17 4 C 0 6078103 D Common Stock 6078103 0 I See Footnotes Series B Convertible Preferred Stock 2019-09-17 4 C 0 1053204 D Common Stock 1053204 0 I See Footnotes Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date. Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date. Represents shares purchased in the Issuer's initial public offering. Represents shares held directly by BC SW, L.P. Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Jeffrey Schwartz is a director of the Issuer. Bain Capital Life Sciences Investors, LLC, By: /s/ Jeffery L. Schwartz, Name: Jeffery L. Schwartz, Title: Managing Director 2019-09-19 BC SW, L.P., By: Bain Capital Life Sciences Investors, LLC, its general partner, By: /s/ Jeffery L. Schwartz, Name: Jeffery L. Schwartz, Title: Managing Director 2019-09-19 /s/Jeffery L. Schwartz 2019-09-19 /s/ Adam Koppel 2019-09-19